中访网数据 北京双鹭药业股份有限公司今日发布公告，其参股公司长风药业股份有限公司计划于2025年10月8日在香港联合交易所主板正式挂牌上市，股份代码为02652.HK。根据全球发售安排，长风药业此次共发售4119.8万股，发售价定为每股14.75港元。本次发行完成后，双鹭药业将持有长风药业约1516.57万股股份，占其发行后总股本的3.68%。根据相关会计准则，双鹭药业持有的这部分股权被分类为以公允价值计量且其变动计入当期损益的金融资产。长风药业的成功上市预计将对双鹭药业2025年度的财务状况和经营成果产生积极影响。双鹭药业所持股份自长风药业上市之日起设有12个月的禁售期。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.